Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by recurrent episodes of inflammation and ulceration of the colon's mucosal lining. Probiotics, such as Lactobacillus casei, have emerged as potential therapeutic agents for UC due to their anti-inflammatory and immunomodulatory properties. This placebo-controlled study aimed to assess the impact of Lactobacillus casei probiotic supplementation on patients with mild to moderate UC. A randomized, double-blind trial was conducted involving UC patients who received either Lactobacillus casei probiotics or a placebo for a specified duration. Disease activity, clinical symptoms, quality of life, and inflammatory markers were evaluated. The study's findings provide valuable insights into the efficacy of Lactobacillus casei probiotics as a complementary therapy for UC management.